Investigational drug · Phase 2
VTX3232
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Idiopathic Parkinson Disease, Obesity.
Phase 2Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
0 still active
All registered trials
3
Any phase or sponsor naming "VTX3232"
First trial start
2024
Aug 8, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VTX3232", any sponsor or status.
Conditions studied
As listed on its trial records.
- Idiopathic Parkinson Disease
- Obesity
Approved drugs for the same conditions: Obesity and weight management · Parkinson's disease · Cardiovascular and metabolic · Neurology
Largest trials
Live from ClinicalTrials.gov: studies naming "VTX3232" as an intervention, largest first.
- Phase 2a Placebo-Controlled Study of VTX3232 Alone or in Combination With Semaglutide in ObesityPivotal-lookingCompleted
Zomagen Biosciences Ltd.Industry
NCT06771115 · 175 participants · Start Jan 7, 2025 · Primary completion Sep 10, 2025
Drug: Placebo; VTX3232 30 mg and 2 more · For: Obesity
Sites: Birmingham, Alabama; Lake Forest, California; Long Beach, California · 14 sites in all
Eli Lilly and CompanyEli Lilly (LLY)
NCT07867340 · 96 participants (planned) · Start Sep 29, 2026 · Primary completion Jan 2027
Drug: LY5625573; Midazolam and 1 more · For: C-Reactive Protein
Sites: Los Alamitos, California; Dallas, Texas; Singapore, Singapore
Zomagen Biosciences Ltd.Industry
NCT06556173 · 11 participants · Start Aug 8, 2024 · Primary completion Apr 4, 2025
Drug: VTX3232 · For: Idiopathic Parkinson Disease
Sites: New Haven, Connecticut
Newest research
PubMed records naming it or its code names, newest first.
- NLRP3 inhibition by VTX3232 tempers inflammation resulting in reduced body weight, hyperglycemia, and hepatic steatosis in obese male mice.
Bultinck J, Yuan S, Cantuti-Castelvetri L, et al. · Mol Metab 2026
Also in development for Idiopathic Parkinson Disease
- NEU-411Phase 21 trial
Neuron23 Inc. · Parkinson Disease, Parkinson, Idiopathic Parkinson Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.